InnumeSensor virus cell background

Our Company

ImmuneSensor Therapeutics is a clinical-stage biotechnology company led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of disease. Leveraging the incredible versatility and therapeutic potential of the cGAS-STING pathway, we are focused on discovering and developing novel medicines that address both cancers and autoimmune diseases. Our growing pipeline includes STING agonists, designed to elicit anticancer immunity, as well as cGAS antagonists, which work to suppress autoimmunity.

Pioneers of cGAS/cGAMP

Our History

ImmuneSensor was founded based on the seminal research conducted by Dr. Zhijian “James” Chen at the University of Texas, Southwestern (UTSW). In 2012, his groundbreaking discovery of the cyclic GMP-AMP synthases (cGAS) enzyme and the secondary messenger, cyclic GMP-AMP (cGAMP), quickly spawned the scientific community’s interest and subsequent research into the role of the cGAS-STING pathway in innate immunity. The importance of the pathway in activating the immune system and its broad applicability in many diseases is now widely recognized.

Since our Company’s founding and in-licensing of our intellectual property portfolio from UTSW shortly thereafter, our team has built a promising pipeline of STING agonists and cGAS inhibitors with first- and best-in-class potential.

Company Milestones

Our Facility

Our headquarters and lab facilities are based in Dallas, Texas, a short distance from the world-renowned UTSW medical center. ImmuneSensor’s team of passionate and highly talented biotech professionals is proud to collaborate alongside global researchers and investigators, clinical trial facilities, corporate partners and contract research organizations.